Study: Sotatercept in Combined Therapy Can Improve PAH Outcomes

2022-10-26T12:40:39-04:00October 26th, 2022|

Results of a Phase 3 study showed that sotatercept added to FDA-approved therapy improved the primary endpoint in six-minute walk distance and secondary efficacy outcome measures. The Phase 3 STELLAR trial evaluated the safety and efficacy of sotatercept for adults with pulmonary arterial hypertension.